5.32
1.92%
+0.10
Editas Medicine Inc stock is currently priced at $5.32, with a 24-hour trading volume of 1.35M.
It has seen a +1.92% increased in the last 24 hours and a -26.32% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.20 pivot point. If it approaches the $5.36 resistance level, significant changes may occur.
Previous Close:
$5.22
Open:
$5.25
24h Volume:
1.35M
Market Cap:
$437.49M
Revenue:
$78.12M
Net Income/Loss:
$-153.22M
P/E Ratio:
-1.7973
EPS:
-2.96
Net Cash Flow:
$-136.90M
1W Performance:
-3.10%
1M Performance:
-26.32%
6M Performance:
-18.28%
1Y Performance:
-32.66%
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 Hurley Street, Cambridge, MA
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Dec-13-22 | Initiated | Citigroup | Neutral |
Dec-06-22 | Resumed | Credit Suisse | Neutral |
Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
Sep-29-22 | Initiated | BofA Securities | Neutral |
Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
Sep-24-21 | Initiated | Stifel | Hold |
Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
Aug-09-21 | Upgrade | Truist | Hold → Buy |
Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
Jun-04-21 | Resumed | Robert W. Baird | Outperform |
May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
Apr-16-21 | Initiated | Goldman | Sell |
Mar-22-21 | Initiated | Credit Suisse | Outperform |
Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
Feb-26-21 | Downgrade | Truist | Buy → Hold |
Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Nov-03-20 | Initiated | Robert W. Baird | Underperform |
Jun-18-20 | Resumed | SunTrust | Buy |
Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Oct-10-18 | Initiated | Guggenheim | Neutral |
Sep-21-18 | Initiated | Raymond James | Outperform |
May-15-18 | Reiterated | Chardan Capital Markets | Buy |
Feb-13-18 | Initiated | CLSA | Underperform |
Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
Jul-14-17 | Initiated | SunTrust | Hold |
Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
Jun-02-16 | Initiated | Jefferies | Hold |
Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
Feb-29-16 | Initiated | JP Morgan | Neutral |
Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire Inc.
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
Zacks Investment Research
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
The Motley Fool
1 Beaten-Down Stock With 55% Upside, According to Wall Street
The Motley Fool
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
The Motley Fool
Editas Medicine Inc Stock (EDIT) Financials Data
Editas Medicine Inc (EDIT) Revenue 2024
EDIT reported a revenue (TTM) of $78.12 million for the quarter ending December 31, 2023, a +296.34% rise year-over-year.
Editas Medicine Inc (EDIT) Net Income 2024
EDIT net income (TTM) was -$153.22 million for the quarter ending December 31, 2023, a +30.49% increase year-over-year.
Editas Medicine Inc (EDIT) Cash Flow 2024
EDIT recorded a free cash flow (TTM) of -$136.90 million for the quarter ending December 31, 2023, a +24.56% increase year-over-year.
Editas Medicine Inc (EDIT) Earnings per Share 2024
EDIT earnings per share (TTM) was -$2.05 for the quarter ending December 31, 2023, a +36.14% growth year-over-year.
Editas Medicine Inc Stock (EDIT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Mei Baisong | SVP, CHIEF MEDICAL OFFICER |
Mar 04 '24 |
Sale |
9.42 |
20,327 |
191,425 |
141,543 |
Eaton Bruce | EVP, CBO AND CTO |
Dec 05 '23 |
Sale |
10.90 |
103 |
1,122 |
74,791 |
Eaton Bruce | EVP, CBO AND CTO |
Nov 14 '23 |
Sale |
8.21 |
695 |
5,706 |
74,894 |
Eaton Bruce | EVP, CBO AND CTO |
Nov 07 '23 |
Sale |
8.40 |
139 |
1,168 |
75,589 |
Eaton Bruce | EVP, CBO AND CTO |
Sep 06 '23 |
Sale |
8.82 |
103 |
908 |
75,728 |
Eaton Bruce | EVP, CBO AND CTO |
Aug 11 '23 |
Sale |
8.59 |
702 |
6,033 |
75,831 |
Eaton Bruce | EVP, CBO AND CTO |
Aug 08 '23 |
Sale |
8.39 |
141 |
1,183 |
76,533 |
Mei Baisong | SVP, CHIEF MEDICAL OFFICER |
Jul 19 '23 |
Sale |
8.80 |
4,317 |
37,990 |
72,055 |
O'Neill Gilmore Neil | CEO |
Jun 05 '23 |
Sale |
9.50 |
6,486 |
61,638 |
130,169 |
Eaton Bruce | EVP, CBO AND CTO |
Jun 05 '23 |
Sale |
9.50 |
105 |
998 |
76,674 |
About Editas Medicine Inc
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Cap:
|
Volume (24h):